Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Half-dose Ticagrelor Monotherapy vs Standard DAPT in CCS After PCI
NCT07622056Phase 4Completed
- Sponsor
- Kaohsiung Veterans General Hospital
- Start
- Jan 2024
- Primary completion
- Dec 2024
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ticagrelor in Chronic Coronary Syndrome (CCS) (3 arms), sponsored by Kaohsiung Veterans General Hospital. Primary endpoint: Change in P2Y12 reaction units (PRU) at 14 days. Started Jan 2024; status: completed.
02
Drugs
ticagrelor
03
Conditions
Chronic Coronary Syndrome (CCS)
Beyond the preview
Go deeper on NCT07622056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07622056.